鶹ýӰ

Meeting Coverage

ASCO Expert Roundtable: DLBCL

Expert Roundtable from the American Society of Clinical Oncology

Experts Discuss Breakthroughs in Large B-Cell Lymphoma at ASCO Annual Meeting

Loretta Nastoupil, MD, leads a discussion on innovative treatments and future directions

image

Latest ASCO Expert Roundtable: DLBCL Meeting Coverage

Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results

R-CHOP plus venetoclax falls short, while R-CHOP with HDAC inhibitor shows promise

July 2, 2024
Combo of Approved Agents Active in High-Risk Large B-Cell Lymphoma

Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients

June 25, 2024
Three-Drug Regimen Shows OS Benefit in Third-Line DLBCL

Loretta Nastoupil, MD, leads a discussion on the ECHELON-3 trial results

June 17, 2024
Antibody-Drug Conjugate Targeting ROR1 Shows Activity in DLBCL

Ian Flinn, MD, PhD, leads a discussion on the promising early data for zilovertamab vedotin

July 6, 2023
Bispecific Antibodies in Relapsed/Refractory DLBCL

Ian Flinn leads a discussion on epcoritamab, which was recently FDA approved

June 29, 2023
Second-Line CAR-T Improves Survival in Large B-Cell Lymphoma

Ian Flinn, MD, PhD, leads a discussion on ZUMA-7 and the upcoming ZUMA-23 with the study authors

June 22, 2023
Including Polatuzumab Vedotin in First-Line DLBCL Treatment

Ian Flinn, MD, PhD, leads a discussion on the future successors to the current standard of care

June 15, 2023

Latest Oncology/Hematology Meeting Coverage